

# Midatech Pharma PLC

14:10 15 May 2019

## Midatech Pharma primed for a busy year

- **Now a pure-play R&D company**
- **Has three breakthrough technologies**
- **Two drugs in clinical trials**

### What the company does

R&D company Midatech is developing a range of improved chemo-therapies and new immuno-therapeutics using its three drug delivery platforms. Each of the technologies is focused on improved delivery and distribution of medicines to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.

**Q-Sphera** is a polymer microsphere innovation used to prolong and control the release of therapeutics over an extended period of time -from weeks to months.

**MidaCore** is the company's gold nanoparticle product used for targeting sites of disease at the nanoscale, usually chemotherapy, but also the new breed of immunotherapies.

**MidaSolve** is used to dissolve otherwise insoluble drugs so they can be administered in liquid form directly and locally into tumours.

It has three drugs in or entering the clinic treating carcinoid cancer, acromegaly (a hormonal disorder), brain cancer in children, and type-1 auto-immune diabetes (see below).

**Price:** 6.845p

**Market Cap:** £28.02M

### 1 Year Share Price Graph



May 2018 November 2018 May 2019

### Share Information

**Code:** MTPH

**Listing:** AIM

**52 week High Low**  
39.20p 2.45p

**Sector:** Pharmaceuticals

**Website:** [www.midatechpharma.com](http://www.midatechpharma.com)

### Company Synopsis:

*Midatech is an international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.*

### Author:

**Proactive Investors Ltd**

+44 (0)207 989 0813

action@proactiveinvestors.com

### Inflexion points

Last month Midatech said it had begun a "new chapter" where it is aiming to provide investors with two years packed with news flow. After selling its US commercial business late last year, the company is now fully focused on developing its drugs pipeline, with the company's two lead drugs in human clinical trials.

With MTD201 (Q-Sphera technology) has taken an existing drug for acromegaly and improved its efficiency and precision. After an early-phase clinical trial it must decide whether to pursue a differentiated product with a distinct clinical profile compared with the existing medication, or to establish an interchangeable alternative to it. Midatech expects to finalise that decision soon, ahead of the next clinical programme set for the second-half of this year. If this is successful, MTD201 could be submitted for marketing authorisation in 2021.

MTX110 (MidaSolve). A read-out from a phase I dose-escalating and safety study on children with brain cancer is expected sometime this year. "Results to date have been encouraging and show that the therapy is well tolerated," the company said recently. "This phase will also establish the recommended dose to be used in the follow-on phase II efficacy component of the study programme, with the objective of assessing patient survival rates after 12 months. It would be wonderful to make a difference to patients and families dealing with this shattering disease."

In March firm said the Spanish government had conditionally approved a €6.6mIn Reindustrialisation, or Reindus loan that will be used to help commercialise its flagship drug. In all, the group has received around €8.5mIn of public backing towards the estimated €16mIn costs to build a plant in Bilbao to manufacture its MTD201 Q-Octreotide development product. Chief executive Craig Cook said the Reindus loan would provide "a real boost" to the commercial manufacturing scale-up scheduled over the next 18-24 months in Bilbao.

Chief executive Craig Cook said...

"2018 was a year of strategic refocusing of the business, with Midatech becoming a pure-play R&D company following the divestment of our US commercial operation in November, a major milestone for the group. We believe the company has entered a new chapter in its growth as a streamlined R&D focused business with in-house manufacturing. We are now delivering on clinical milestones, with strong clinical data, and a compelling pipeline for our proprietary drug delivery platforms, all of which are now into the clinic."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.